BeyondSpring (BYSI) Non-Current Deffered Revenue (2020 - 2026)
BeyondSpring (BYSI) posted Non-Current Deffered Revenue of $29.0 million for Q1 2026, up 1.38% sequentially from $28.6 million in Q4 2025, and up 5.2% YoY from $27.6 million in Q1 2025.
BeyondSpring (BYSI) Non-Current Deffered Revenue (2020 - 2026) Analysis & Trends
BeyondSpring has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $29.0 million in Q1 2026.
- Quarterly Non-Current Deffered Revenue rose 5.2% year-over-year to $29.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.0 million (up 5.2% YoY) and the FY2025 annual result came in at $28.6 million, up 4.38% from the prior year.
- Non-Current Deffered Revenue improved to $29.0 million in Q1 2026 per BYSI's latest filing, from $28.6 million in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $35.8 million in Q2 2022 and troughed at $27.4 million in Q4 2024.
- A 5-year average of $30.2 million and a median of $28.6 million in 2025 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue surged 393.28% in 2022, then slipped 17.68% in 2023.
- Over 5 years, Non-Current Deffered Revenue stood at $34.2 million in 2022, then retreated by 17.68% to $28.2 million in 2023, then dropped by 2.73% to $27.4 million in 2024, then climbed by 4.38% to $28.6 million in 2025, then rose by 1.38% to $29.0 million in 2026.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $29.0 million, $28.6 million, and $28.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | 29.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.48 Mn |
| Mar 31, 2026 | 28.99 Mn |
| Dec 31, 2025 | 28.60 Mn |
| Sep 30, 2025 | 28.09 Mn |
| Jun 30, 2025 | 27.92 Mn |
| Mar 31, 2025 | 27.56 Mn |
| Dec 31, 2024 | 27.40 Mn |
| Jun 30, 2024 | 32.34 Mn |
| Dec 31, 2023 | 28.17 Mn |
| Jun 30, 2023 | 33.53 Mn |
| Dec 31, 2022 | 34.22 Mn |
| Jun 30, 2022 | 35.76 Mn |
| Dec 31, 2021 | 37.94 Mn |
| Sep 30, 2021 | 37.77 Mn |
| Jun 30, 2021 | 7.25 Mn |
| Mar 31, 2021 | 7.59 Mn |
| Dec 31, 2020 | 7.93 Mn |